Literature DB >> 12930732

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

Timm H Westhoff, Friederike Jochimsen, Alexander Schmittel, Marina Stoffler-Meilicke, Jurgen H Schafer, Walter Zidek, Wolfram H Gerlich, Eckhard Thiel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12930732     DOI： 10.1182/blood-2003-05-1403

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  52 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 2.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

3.  Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.

Authors:  Kiarash Kojouri; James N George
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

Review 4.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

5.  Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy.

Authors:  Jun Inoue; Yasuteru Kondo; Yuta Wakui; Takayuki Kogure; Tatsuki Morosawa; Yasuyuki Fujisaka; Teruyuki Umetsu; Satoshi Takai; Takuya Nakamura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2016-02-26

Review 6.  Genetic variation of occult hepatitis B virus infection.

Authors:  Hui-Lan Zhu; Xu Li; Jun Li; Zhen-Hua Zhang
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

7.  Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.

Authors:  Toshihiko Ando; Kensuke Kojima; Hiroshi Isoda; Yuichiro Eguchi; Takashi Honda; Masatoshi Ishigami; Shinya Kimura
Journal:  Int J Hematol       Date:  2015-04-05       Impact factor: 2.490

8.  Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients.

Authors:  Xiangsheng Xu; Qinghua Shang; Xinyue Chen; Weimin Nie; Zhengsheng Zou; Ang Huang; Ming Meng; Lei Jin; Ruonan Xu; Ji-Yuan Zhang; Junliang Fu; Lifeng Wang; Zirong Tang; Yunbo Xie; Xiaoming Yang; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2015-04-06       Impact factor: 11.530

9.  A case of hepatitis B reactivation in an anti-HBs positive, anti-HBc positive non-Hodgkin's lymphoma patient.

Authors:  Chunchen Wu; Hui Shi; Mengji Lu; Yang Xu; Xinwen Chen
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

Review 10.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.